Principal Financial Group Inc. Acquires 21,356 Shares of Catalent, Inc. (CTLT)
Principal Financial Group Inc. increased its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 4.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 558,754 shares of the company’s stock after purchasing an additional 21,356 shares during the period. Principal Financial Group Inc. owned approximately 0.45% of Catalent worth $22,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of CTLT. Janus Henderson Group PLC purchased a new position in shares of Catalent during the second quarter worth $239,629,000. BlackRock Inc. increased its holdings in Catalent by 15.2% in the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after buying an additional 2,316,849 shares in the last quarter. AJO LP purchased a new position in Catalent in the second quarter valued at $26,130,000. Macquarie Group Ltd. increased its holdings in Catalent by 60.2% in the second quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock valued at $62,715,000 after buying an additional 671,429 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Catalent in the second quarter valued at $23,092,000. 94.69% of the stock is owned by hedge funds and other institutional investors.
CTLT has been the subject of a number of recent analyst reports. BidaskClub cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a report on Tuesday, August 22nd. William Blair reaffirmed an “ourperform” rating on shares of Catalent in a report on Tuesday, August 29th. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $40.00 price objective (up previously from $38.00) on shares of Catalent in a report on Tuesday, August 29th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.11.
Shares of Catalent, Inc. (CTLT) opened at $38.92 on Thursday. Catalent, Inc. has a 52-week low of $22.94 and a 52-week high of $43.39. The stock has a market cap of $5,169.56, a PE ratio of 27.21, a PEG ratio of 2.50 and a beta of 1.49. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49.
Catalent (NYSE:CTLT) last announced its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same quarter last year, the business earned $0.16 earnings per share. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. sell-side analysts forecast that Catalent, Inc. will post 1.46 EPS for the current year.
In other news, SVP Christine Dolan sold 1,594 shares of Catalent stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Uwe Roehrhoff bought 7,500 shares of the company’s stock in a transaction dated Tuesday, November 21st. The stock was bought at an average price of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is owned by company insiders.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.